These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1331 related articles for article (PubMed ID: 24315313)

  • 21. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
    Rodloff AC; Dowzicky MJ
    Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.
    Kehl SC; Dowzicky MJ
    J Clin Microbiol; 2015 Apr; 53(4):1286-93. PubMed ID: 25653413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial.
    Brandon M; Dowzicky MJ
    J Clin Microbiol; 2013 Jul; 51(7):2371-8. PubMed ID: 23678070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
    Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
    J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
    Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
    Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
    Tärnberg M; Nilsson LE; Dowzicky MJ
    Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA; Koch KM; Dowzicky MJ
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009).
    Andrasevic AT; Dowzicky MJ
    Int J Antimicrob Agents; 2012 Feb; 39(2):115-23. PubMed ID: 22189391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.